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Abstract 
Purpose: To examine the relationship between geographic atrophy (GA) progression and 
choroidal thickness (CT) and cataract surgery. 
Methods: Previously recorded Fundus Autofluorescence (FAF) and Spectral-Domain 
Optical Coherence Tomography (SD-OCT) images of patients with GA were analysed and GA 
area and choroidal thickness were measured in different moments in time. Subfoveal CT was 
measured in all eyes and in those with the largest lesion outside the fovea an additional 
measurement was made at the centre of the lesion. GA area progression and CT progression 
were calculated based in these measurements. The eyes were then divided in three groups 
according to their phakic status:  pseudophakic, surgery performed during the study and phakic. 
Statistically significant differences between these groups in GA area progression were 
calculated. Differences in GA progression in the second group before and after surgery were 
also analysed. 
Results: Median and mean GA progression rates in the three groups were 0.05/0.10; 
0.13/0.13 and 0.08/0.11 mm2/month respectively (p=0.154). In the patients intervened during 
the study, mean GA progression rates before and after surgery were 0.09±0.12 mm2/month and 
0.08±0.06 mm2/month respectively (p=0.874). We found no association between initial 
subfoveal CT or initial largest lesion CT and GA progression (p=0.139; p=0.910). 
Conclusion: We found no association between geographic atrophy progression and 
choroidal thickness or phakic or pseudophakic status. 
  
Introduction 
Age-related Macular Degeneration (AMD) is a leading cause of blindness worldwide 
especially in developed countries. It affects primarily older patients, and is divided in a “wet” 
and “dry” form due to different manifestations and prognosis. (Ambati and Fowler 2012, Erke, 
Bertelsen et al. 2012, Owen, Jarrar et al. 2012)  
Geographic atrophy (GA) is the end-stage of dry AMD. Its hallmark is a progressive 
degeneration of the retinal pigment epithelium (RPE) and photoreceptors. (Gobel, Fleckenstein 
et al. 2011, Ambati and Fowler 2012, Bhutto and Lutty 2012)  Although its course is not as fast 
as in wet AMD, GA can cause some degree of visual impairment and evolve to severe central 
blindness, being responsible for 10% of legal blindness attributed to AMD. (Ambati and Fowler 
2012, Zhou, Ye et al. 2012) Contrary to wet AMD, there is currently no treatment for 
geographic atrophy in a form capable of clearly reversing or slowing the progression of the 
lesions or reversing the symptoms. (Nowak 2006, Ambati and Fowler 2012, Kanagasingam, 
Bhuiyan et al. 2014)   
Fundus autofluorescence (FAF) imaging is a non-invasive imaging method that allows 
topographic mapping of lipofuscin distribution in the RPE cell monolayer in-vivo. Due to the 
absence of RPE lipofuscin, atrophic areas in eyes with GA have a severely reduced signal. 
Using image software it is possible to quantify the area of GA and analyse the progression of 
the lesions. (Gobel, Fleckenstein et al. 2011, Schmitz-Valckenberg, Brinkmann et al. 2011, 
Khanifar, Lederer et al. 2012, Kanagasingam, Bhuiyan et al. 2014) 
The understanding of the underlying mechanisms of disease is far from complete and several 
theories have been proposed. (Nowak 2006, Ambati and Fowler 2012, Bhutto and Lutty 2012, 
Parmeggiani, Romano et al. 2012, Zhou, Ye et al. 2012, Coleman, Silverman et al. 2013)  
Genetics most certainly plays an important role, as well as environmental factors such as 
smoking. (Fraser-Bell, Wu et al. 2006, Nowak 2006, Ambati and Fowler 2012, Parmeggiani, 
Romano et al. 2012) 
Cataract is the most common ophthalmologic disease of elderly people. It is characterized by 
“blurred” vision caused by opacity of the crystalline lens due to its degeneration accompanied 
by water and elasticity loss. (Bockelbrink, Roll et al. 2008, Chew, Sperduto et al. 2009, 
Casparis, Lindsley et al. 2012) 
Phacoemulsification with intra-ocular lens implantation is one of the most performed 
surgeries, consisting of the removal of the opacified lens and replacement by an artificial lens 
implant. (Cugati, Mitchell et al. 2006, Bockelbrink, Roll et al. 2008, Casparis, Lindsley et al. 
2012, Wang, Fong et al. 2012)  
Some previous studies suggested a relation between cataract surgery and the progression of 
AMD, while others found no such association. (Cugati, Mitchell et al. 2006, Bockelbrink, Roll 
et al. 2008, Chew, Sperduto et al. 2009, Fraser-Bell, Choudhury et al. 2010, Casparis, Lindsley 
et al. 2012, Wang, Fong et al. 2012, Zhou, Ye et al. 2012) 
The choroid is a vascular layer of the eye that lies beneath the retina. It is responsible for the 
vascular supply of the outer retina, including the RPE. (Ikuno, Kawaguchi et al. 2010, 
Manjunath, Goren et al. 2011) 
It has been previously proposed that choroid might play a role in the development of AMD, 
but the matter remains controversial. (Ikuno, Kawaguchi et al. 2010, Manjunath, Goren et al. 
2011, Bhutto and Lutty 2012, Coleman, Silverman et al. 2013)  
With the use of Spectral-Domain Optical Coherence Tomography (SD-OCT), especially 
using the Enhanced Depth Imaging technique it is now possible to obtain detailed, images from 
the choroid allowing its measurement. (Spaide, Koizumi et al. 2008, Gobel, Fleckenstein et al. 
2011, Manjunath, Goren et al. 2011, Kanagasingam, Bhuiyan et al. 2014)  
Because cataract surgery is a frequent procedure in patients with dry AMD it is important to 
understand its effects and those of intra-ocular lens implantation on the progression of the 
geographic atrophy. We also correlated progression of geographic atrophy with choroidal 
thickness. 
 
Methods  
This retrospective study analysed patients that are being followed in the Retina Department 
of our hospital and are being followed by autofluorescence and SD-OCT.   
In our department, patients with geographic atrophy are imaged using the Spectralis® 
Heidelberg® that allows the acquisition of both fundus autofluorescence and SD-OCT. SD-
OCT and FAF  images recorded in routine clinical practice were retrospectively analysed using 
the Heidelberg SPECTRALIS
®
 Software. 
We selected patients’ eyes that had at least 2 images and at least 6 months of follow-up. 
Exclusion criteria included: areas of geographic atrophy larger than the square that can be 
obtained from the spectralis® AF image, aphakic status, presence of other retinal disease such 
as wet AMD or diabetic retinopathy. 
To measure the GA area, Region Finder
TM
 (Heidelberg Engineering) software was used. 
With this software atrophic areas are outlined on the screen using the mouse-driven cursor. The 
software allows a direct export of FAF images from the database, semi-automated detection of 
atrophic areas by shadow correction, vessel detection, selection of seed points and comparison 
of images from the same patient. (Gobel, Fleckenstein et al. 2011, Schmitz-Valckenberg, 
Brinkmann et al. 2011) The software then compares the sequential images for each patient and 
automatically calculates the selected areas and calculates growth rates. 
Choroidal thickness measurements were performed manually by the same single observer 
(MT) using the calipers provided by the Spectralis® Heidelberg® software. Choroidal thickness 
was measured from the outer limit of the retinal pigment epithelium to the choroidal-scleral 
junction. A single vertical measurement was made under the fovea. When the largest lesion was 
not on the fovea, an additional measurement was also made under the centre of the largest 
lesion. 
Data from each patient regarding the phakic status of each eye (phakic versus pseudophakic) 
was obtained from the patients’ medical records. All patients that had previous cataract surgery 
were labelled pseudophakic, and patients that had not had any cataract surgery were considered 
phakic. 
The eyes were then divided in three groups according to their phakic status:  pseudophakic, 
surgery performed during the study and phakic. Statistically significant differences between 
these groups in GA area progression were calculated. Differences in GA progression in the 
second group before and after surgery were also analysed. Statistical analysis was performed 
using Student’s t-test, paired sample t-test, one-way Anova and Pearson’s correlation 
coefficient. Data normality was calculated using Shapiro-Wilk test. For non-normal data the 
Kruskal-Wallis and Mann-Whitney tests were used. Statistical significance was considered 
when p < 0.05. 
 
Results 
The initial database contained a total of 118 eyes from 59 patients. Of these eyes, 56 (47%) 
were included and 62 (53%) excluded from this study. The exclusion criteria were the 
following: lack of the necessary number of images in 32 eyes (27%); presence of wet AMD in 
18 (15%); no evidence of GA lesions in 5 (4%); other ophthalmologic lesions in 4 (3%) and 
lesions larger than window size in 3 eyes (3%).  
Of the 56 accepted eyes, 17 were pseudophakic; 35 phakic, and 4 were submitted to surgery 
during the study allowing a comparison of the progression rate of GA before and after the 
procedure. The mean age of the patients was 82±6 years. 26 (46%) eyes were from male 
patients and 30 (54%) from female ones.  
35(63%) patients had bilateral GA; 12(21%) had wet AMD in the fellow eye and 9(16%) had 
no advanced AMD in the fellow eye. The status of the fellow eye had no relation with the GA 
progression rate (p=0.447; Kruskal-Wallis). 
10 eyes had two measurements included, 25 had 3 and 21 had four images, resulting in a 
mean of 3.20 images per eye.  
In 37(66%) eyes the largest lesion was over the fovea while in 19(34%) it was not (Table 1). 
The mean period between the first and last image was 25±12 months. At the first image the 
mean GA area (Table 2) was of 5±6 mm2, the mean subfoveal choroid thickness (CT) was 
175±66 µm and the mean CT under the largest lesion was 183±67 µm. At the last image the 
mean GA area was 7±7 mm2, the mean subfoveal CT was 157±63 µm and the mean CT under 
the largest lesion was 182±80µm.  
Subfoveal choroidal thickness in the first and last images had a weak inverse relation with 
patient age (p=0.026, r= -0.298; p= 0.043, r= -274, Pearson correlation test). 
In relation to the first image, mean GA area variation was 114±160 % mean subfoveal CT 
variation -8±20% (range -50; 54), and mean CT under the largest lesion -7±34%  
The median in GA area progression rate was 0.07 (range: 0.00-0.44) mm2/month; mean 
subfoveal CT progression rate was -0.85±3 µm/month and mean CT progression under the 
largest lesion was -0.48±3 µm/month.  
The relation between initial subfoveal CT or initial largest lesion CT and GA progression 
was not statistically significant (p=0.139; p=0.910, Pearson correlation test). There was no 
statistically significant difference in GA progression between the eyes with foveal or extra-
foveal lesions (p=0.979, Mann-Whitney).  
Regarding the three groups of surgery status (pseudophakic, surgery during the study or 
phakic), the mean ages were 84, 86 and 80 years. In the first category 6 eyes had the largest 
lesion over the fovea and 11 did not, this changed to 3/1 and 28/6 in the other categories. The 
mean follow up periods were 22±3; 32±8 and 25±2 months respectively. The difference in GA 
progression between these groups was not significant (p=0.154, Kruskal-Walis). (Tables 1 and 
2) 
In the 4 eyes intervened during the study, the mean GA progression rate was 0.09±0.12 
mm2/month before cataract surgery and 0.08±0.06 mm2/month after (Table 3). We found no 
statistically significant difference in the progression rate of GA before and after the surgery  
(p=0.874, paired sample T-test). 
 
Discussion 
Several mechanisms and risk factors have been suggested for the development of GA. 
(Fraser-Bell, Wu et al. 2006, Fraser-Bell, Choudhury et al. 2010, Ambati and Fowler 2012, 
Parmeggiani, Romano et al. 2012, Zhou, Ye et al. 2012, Coleman, Silverman et al. 2013) A 
particular attention has been paid to the role of cataract surgery given that cataracts and AMD 
are two of the most common ophthalmologic diseases, especially in the ageing populations. At 
this point, there is no clear association between cataract surgery and the progression of AMD 
(Casparis, Lindsley et al. 2012).  
Our study found no association between geographic atrophy progression rate and phakic 
status. We analysed this association by a group of patients previously submitted to cataract 
surgery with phakic patients and also by comparing progression rates before and after surgery in 
the group submitted to phacoemulsification during the study. Both results were consistent with 
the absence of a worsening of GA provoked by cataract surgery. This is an additional step in the 
argument against the proponents of a positive association between phacoemulsification with 
intra-ocular lens implantation and AMD (Cugati, Mitchell et al. 2006, Fraser-Bell, Choudhury 
et al. 2010) and in favour of those who find no association (Chew, Sperduto et al. 2009, Wang, 
Fong et al. 2012).  
Other studies have also suggested that the problem could be not cataract surgery, but that the 
cataract itself had protective effects either by providing protection against deleterious sun light, 
which has a controversial role in AMD progression, (Cruickshanks, Klein et al. 1993, Delcourt, 
Carrière et al. 2001, Fletcher, Bentham et al. 2008, Yam and Kwok 2013) or by the presence of 
αA-crystallin (Zhou, Ye et al. 2012). In both cases the removal of the cataract and thereby 
removal of the protective mechanism should increase GA progression which was not observed 
in our study. Even though in our retrospective study, we did not quantify the crystalline status of 
the phakic population, with a mean patient age of 82 years, some degree of lenticular 
opacification is expected. Therefore, a protective effect of the cataract, if present, should have 
been observed. 
Even though the number of eyes submitted to surgery during the study was small (4 eyes), 
we could not find a significant difference in the GA progression rate before and after the 
procedure, or any acute retinal or choroidal change detectable on SD-OCT.   
 A difference between this study and most of the previous is its focus on patients already 
with a late stage manifestation of AMD and not in the progression from early stages to late 
stages of AMD.  
This was relevant because we did not find an association between phakic status and GA 
progression. This may mean that it is probably safe to have cataract surgery on patients with 
GA. In our four eyes that had surgery during the study period we did not find any cases of acute 
retinal or choroidal changes caused by the surgery and we did not find any changes in GA 
progression. Even though cataract surgery may not improve visual acuity when the fovea is 
compromised by GA, other benefits of cataract surgery such as improved contrast sensitivity 
may improve the quality of life of these patients without compromising the retinal disease.  
Furthermore a mean time between first and last images of 25 months and a mean of 3.2 
pictures per eye allowed us to observe important patterns in lesion progression. 
 It is possible that in these older patients with advanced disease the effects of lens removal 
are different from younger early stage patients. Likewise, we had no access to data of lesion 
progression before the surgery in the group of patients operated before the beginning of the 
study which could have provided further useful information about GA and CT progression rates. 
In this study we also tried to examine the relation between GA progression and CT as it had 
been suggested that choroidal dysfunction could be related with AMD (Coleman, Silverman et 
al. 2013, Sigler and Randolph 2013). Similarly we found no supporting evidence for these 
hypotheses as both baseline subfoveal CT and largest lesion CT were not associated with any 
change in GA progression. This was true for all the three groups. As a consequence we cannot 
support the role of CT as cause or a marker of GA progression. However, choroidal 
abnormalities that cannot be detected by SD-OCT may play an important role in GA 
progression. 
An interesting finding regarding the choroid was a mean change in subfoveal choroidal 
thickness of –8 % and of -7% in largest lesion CT in a mean period of only 25 months. Even 
though this was not a uniform tendency, with 16 eyes out of 56 showing an increase in 
subfoveal CT and 5 out of 17 in largest lesion CT, to our knowledge it is the first time such a 
significant choroidal thinning in a relatively short period is described. The implications of this 
are at the moment unknown. The reduction in choroidal thickness could either be a consequence 
or a cause of GA progression; or it might not even be related. 
This study had some important limitations. Its retrospective nature, with restraints in the 
available data, and the small number of eyes submitted to surgery during the study were the 
most relevant. Data regarding sun light exposure, anti-oxidant intake and smoking was not 
accessible and would have been important in controlling biases. The reduced number of eyes 
undergoing phacoemulsification with the required number of images may be partly due to the 
SD-OCT and autofluorescence imaging being available only in 2009. Further studies will 
accordingly be able to include more patients allowing stronger conclusions. 
Although we could not identify any predicting factor of GA progression and found no 
association with cataract surgery we acknowledge the need for further investigation in this area 
with a higher number of individuals included, and taking into account a larger number of 
relevant variables as those above mentioned. The used method of analysing several sequential 
images of the same eye may be particularly indicated as it allows differentiation between natural 
disease progression and influence of external factors.  
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Tables 
 
Table 1 
 
Phakic Status  
Pseudophakic S. during the study Phakic Total 
Eyes, n 17 4 35 56 
Gender 6M 11F 1M 3F 19M 16F 56 
Fellow-eye AMD 5N 10GA 2W 0N 2GA 2W 4N 23GA 8W 56 
LL out of Fovea (n) 11 (65%) 1 (25%) 7 (20%) 19 (34%) 
 
Table 1: Number of eyes, gender, status of the fellow eye and largest lesion outside the fovea, by phakic 
status. M:  male, F: female, AMD: age-related macular degeneration, N: No AMD lesion, GA: geographic 
atrophy, W: wet AMD, LL: largest lesion; S: Surgery. 
 
Table 2: Geographic atrophy area at the first image, at the last image, and progression rate per month. 
Median is shown for GAA PR because of its non-normal distribution. Med: median, stDv: standard 
deviation, GAA: geographic atrophy area, PR: progression rate.*The differences in progression rates 
between the three groups were not statistically significant.  
 
 
Table 3: Geographic atrophy area progression rate and subfoveal choroidal thickness progression rate, 
before and after surgery. stDv: standard deviation, GAA PR: geographic atrophy area progression rate, SF 
CT PR: subfoveal choroidal thickness progression rate. 
Table 2 
 
Phakic Status 
Pseudophakic S. during the study Phakic 
Min Max Mean Med stDv Min Max Mean Med stDv Min Max Mean Med stDv 
GAA first 
image (mm2) 
0.1 16.3 5.4 _ 5.7 2.5 6.3 4.3 _ 2.0 0.0 32.1 4.9 _ 5.8 
GAA last 
image (mm2) 
0.3 17.5 7.4 _ 6.1 6.0 12.1 8.4 _ 2.7 1.2 47.4 7.4 _ 7.9 
GAA PR 
(mm2/month) 
0.00 0.40 0.10 0.05 0.12 0.12 0.13 0.13 0.13 0.003 0.02 0.44 0.11 0.08 0.09 
Table 3 
 Eyes submited to surgery During the Study (4 patients) 
Before Surgery After Surgery 
Min Max Mean stDv Min Max Mean stDv 
GAA PR 
(mm2/month) 
-
0.07 
0.19 0.09 
0.12 
 
0.03 0.17 0.08 0.06 
SF CT PR 
(µm/month) 
-3.9 -6 -0.4 
2.4 
-1.1 20 4.7 10.2 
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